A Bayesian design for phase I cancer therapeutic vaccine trials
Phase I clinical trials are the first step in drug development to test a new drug or drug combination on humans. Typical designs of Phase I trials use toxicity as the primary endpoint and aim to find the maximum tolerable dosage. However, these designs are poorly applicable for the development of cancer therapeutic vaccines because the expected safety concerns for these vaccines are not as much as cytotoxic agents. The primary objectives of a cancer therapeutic vaccine phase I trial thus often include determining whether the vaccine shows biologic activity and the minimum dose necessary to achieve a full immune or even clinical response. In this paper, we propose a new Bayesian phase I trial design that allows simultaneous evaluation of safety and immunogenicity outcomes. We demonstrate the proposed clinical trial design by both a numeric study and a therapeutic human papillomavirus vaccine trial.
Source: Statistics in Medicine - Category: Statistics Authors: Chenguang Wang,
Gary L. Rosner,
Richard B.S. Roden Tags: RESEARCH ARTICLE Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Cervical Cancer Vaccine | Clinical Trials | Gardasil | Genital Warts | HPV Testing | Human Papillomavirus (HPV) | Statistics | Study | Toxicology | Vaccines